Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Safety of CE-Iohexol vs Omnipaque in Impaired Renal Function
NCT04627831Phase 2Withdrawn
- Sponsor
- Ligand Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of iohexol in coronary artery disease (CAD) (2 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Incidence of contrast-induced acute kidney injury at 7 days. Planned start Jan 2022; status: withdrawn.
02
Drugs
iohexol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04627831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627831.